Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast
Authors:
- 30 November 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 153 (5) , 583-592
Abstract
Objectives To investigate human epidermal growth factor receptor 2 (HER2)-positive nonpleomorphic invasive lobular carcinoma (ILC), which has rarely been addressed. Methods Clinicopathologic characteristics and follow-up of HER2-positive nonpleomorphic ILCs were collected and compared to those of HER2-negative counterparts. Results Twenty-one cases of HER2-positive nonpleomorphic ILCs were identified, 6.3% of the study population. Compared to HER2-negative nonpleomorphic ILC, patients with HER2 positivity were older (P < .05), likely to be hormonal receptor negative (P < .01), and had higher histologic grade and angiolymphatic invasion (P < .01). HER2 positivity in nonpleomorphic ILCs was associated with higher recurrence/metastasis with hazard ratio of 2.03 (P < .05). No patient who received neoadjuvant therapy achieved pathologic complete response, and HER2-targeted therapy tended to reduce recurrence/metastasis in patients with HER2-positive nonpleomorphic ILC. Conclusions Our results highlight the existence of HER2 positivity in nonpleomorphic ILCs and reinforce that HER2 is associated with worse prognosis in nonpleomorphic ILC.Keywords
This publication has 30 references indexed in Scilit:
- Classical-Type Invasive Lobular Carcinoma With HER2 OverexpressionAmerican Journal of Clinical Pathology, 2011
- Suitability of infiltrative lobular breast carcinoma for anti‐human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meetingHistopathology, 2010
- Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studiesDiagnostic Pathology, 2010
- HER2 in well differentiated breast cancer: is testing necessary?Breast Cancer Research and Treatment, 2008
- Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Invasive lobular carcinoma: to grade or not to gradeLaboratory Investigation, 2005
- HER2/neuAmplification in Breast CancerAmerican Journal of Clinical Pathology, 2002
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyStem Cells, 1998
- p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breastEuropean Journal of Cancer, 1997
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987